BY MARKETWIRE
-
Eli Lilly set to join FDA in lawsuit over copycat weight-loss drugs
Eli Lilly does not rely on the United States Fda to be able to take care of a claim submitted by a variety of imitation medicine suppliers in the United States by itself.
-
Gubra signs cooperation agreement with Amylyx Pharmaceuticals
The cooperation includes the advancement of an unique long-acting GLP-1 receptor villain.
-
US could continue equity dominance in 2025
The United States S&P 500 index has actually surpassed the European Stoxx 600 index, to name a few, in 2024. Financial institution claims the distinction is partially as a res…
-
JPMorgan: Novo Nordisk’s plunge on Friday was an overreaction
JPMorgan states Novo Nordisk still has a “far more affordable item” with Cagrisema contrasted to Wegovy regardless of unsatisfactory arise from the Redefine 1 research …
-
GN continues to fight speculators: Uncertainty about Enterprise and tariffs adds pressure
Capitalists are worried concerning whether Donald Trump’s feasible tolls on Chinese items will certainly influence GN in the United States, states expert.
-
Novo Nordisk’s Victoza gets first generic competitor approved in the US
Hikma Pharmaceuticals in the UK has actually been provided authorization to market a common duplicate of Victoza in the United States via its United States subsidiary.
-
President Musk, Dr. Oz and a Kennedy to fight over Novo Nordisk’s Ozempic
An interior battle under the inbound United States head of state might impact Novo Nordisk’s sales.
-
Novo Nordisk nears turning point for weight-loss drugs
Main financial institution sees new generations of therapy as a catalyst for a ”important development increase”.
-
Demant receives EUR 120m loan for hearing aid development
The financing from the European Financial investment Financial institution will certainly go in the direction of Demant’s continuous advancement of future generation listenin…
-
Pfizer investors breathe sigh of relief after 2025 forecast
Anticipated income in 2025 is in between USD 61-64bn.